@article{fdi:010093047,
  title = {{P}reclinical in vivo assessment of the activity of {AZD}7442 anti-{SARS}-{C}o{V}-2 monoclonal antibodies against {O}micron sublineages},
  author = {{D}riouich, {J}.{S}. and {C}ochin, {M}. and {L}ingas, {G}. and {L}uciani, {L}. and {B}aronti, {C}{\'e}cile and {B}ernardin, {O}. and {G}illes, {M}agali and {S}aba {V}illarroel, {P}.{M}. and {M}oureau, {G}. and {P}etit, {P}.{R}. and {D}upont, {A}. and {I}zopet, {J}. and {K}amar, {N}. and {A}utran, {B}. and {P}aintaud, {G}. and {C}aillard, {S}. and {L}e {B}ourgeois, {A}. and {R}ichez, {C}. and {C}ouzi, {L}. and {X}haard, {A}. and {M}arjanovic, {Z}. and {A}vouac, {J}. and {J}acquet, {C}. and {A}nglicheau, {D}. and {C}heminant, {M}. and {N}guyen, {S}. and {T}errier, {B}. and {G}ottenberg, {J}.{E}. and {B}esson, {C}. and {L}etrou, {S}. and {T}ine, {J}. and {M}iantezila {B}asilua, {J}. and {A}ngoulvant, {D}. and {T}ardivon, {C}. and {B}lancho, {G}. and {M}artin-{B}londel, {G}. and {Y}azdanpanah, {Y}. and {M}entr{\'e}, {F}. and {L}{\'e}vy, {V}. and {T}ouret, {F}ranck and {G}uedj, {J}. and {D}e {L}amballerie, {X}. and {N}ougair{\`e}de, {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}herapeutic monoclonal antibodies have been successful in protecting vulnerable populations against {SARS}-{C}o{V}-2. {H}owever, their effectiveness has been hampered by the emergence of new variants. {T}o adapt the therapeutic landscape, health authorities have based their recommendations mostly on in vitro neutralization tests. {H}owever, these do not provide a reliable understanding of the changes in the dose-effect relationship and how they may translate into clinical efficacy. {T}aking the example of {E}vusheld{TM} ({AZD}7442), we aimed to investigate how in vivo data can provide critical quantitative results and project clinical effectiveness. {W}e used the {G}olden {S}yrian hamster model to estimate 90?% effective concentrations ({EC}90) of {AZD}7442 in vivo against {SARS}-{C}o{V}-2 {O}micron {BA}.1, {BA}.2 and {BA}.5 variants. {W}hile our in vivo results confirmed the partial loss of {AZD}7442 activity for {BA}.1 and {BA}.2, they showed a much greater loss of efficacy against {BA}.5 than that obtained in vitro. {W}e analyzed in vivo {EC}90s in perspective with antibody levels measured in a cohort of immunocompromised patients who received 300?mg of {AZD}7442. {W}e found that a substantial proportion of patients had serum levels of anti-{SARS}-{C}o{V}-2 spike protein {I}g{G} above the estimated in vivo {EC}90 for {BA}.1 and {BA}.2 (21?% and 92?% after 1 month, respectively), but not for {BA}.5. {T}hese findings suggest that {AZD}7442 is likely to retain clinical efficacy against {BA}.2 and {BA}.1, but not against {BA}.5. {O}verall, the present study illustrates the importance of complementing in vitro investigations by preclinical studies in animal models to help predict the efficacy of monoclonal antibodies in humans.},
  keywords = {},
  booktitle = {},
  journal = {{B}iomedicine and {P}harmacotherapy},
  volume = {177},
  numero = {},
  pages = {116988 [11 ]},
  ISSN = {0753-3322},
  year = {2024},
  DOI = {10.1016/j.biopha.2024.116988},
  URL = {https://www.documentation.ird.fr/hor/fdi:010093047},
}